BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB) was the recipient of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 2,697,341 shares, a decline of 59.2% from the January 29th total of 6,612,587 shares. Based on an average daily trading volume, of 3,975,081 shares, the short-interest ratio is currently 0.7 days. Approximately 4.8% of the shares of the stock are short sold. Approximately 4.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,975,081 shares, the short-interest ratio is currently 0.7 days.

Hedge Funds Weigh In On BioAtla

Institutional investors and hedge funds have recently bought and sold shares of the company. Woodline Partners LP purchased a new position in BioAtla during the 1st quarter worth approximately $26,000. Acadian Asset Management LLC raised its holdings in shares of BioAtla by 968.9% during the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after purchasing an additional 1,531,994 shares during the last quarter. Acorn Capital Advisors LLC lifted its position in BioAtla by 19.9% during the second quarter. Acorn Capital Advisors LLC now owns 4,835,111 shares of the company’s stock valued at $1,915,000 after purchasing an additional 803,065 shares during the period. Sheets Smith Investment Management purchased a new stake in BioAtla in the third quarter valued at $46,000. Finally, Vanguard Group Inc. increased its holdings in shares of BioAtla by 9.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after purchasing an additional 162,647 shares in the last quarter. 77.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BCAB has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAtla in a report on Friday, January 9th. Rodman & Renshaw initiated coverage on shares of BioAtla in a report on Tuesday, January 13th. They issued a “buy” rating and a $4.00 target price for the company. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, BioAtla has an average rating of “Hold” and an average price target of $4.00.

BioAtla Trading Up 4.5%

Shares of BioAtla stock traded up $0.01 on Friday, hitting $0.25. 2,023,042 shares of the company traded hands, compared to its average volume of 2,780,937. The company has a market cap of $15.74 million, a PE ratio of -0.22 and a beta of 1.10. The stock’s 50 day moving average price is $0.36 and its 200-day moving average price is $0.58. BioAtla has a 52 week low of $0.13 and a 52 week high of $1.43.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.